Exagen Inc.
XGN
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lā¦ read more
Healthcare
Diagnostics & Research
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$9.56
Price-7.90%
-$0.82
1Y
Price
Market Cap
$215.172m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-15.3%
EBITDA Margin-25.8%
Net Profit Margin-18.0%
Free Cash Flow MarginRevenue
$58.862m
+5.8%
1y CAGR+9.0%
3y CAGR+5.3%
5y CAGREarnings
-$16.980m
-12.3%
1y CAGR+24.6%
3y CAGR-0.7%
5y CAGREPS
-$0.89
-7.2%
1y CAGR+27.5%
3y CAGR+4.4%
5y CAGRBook Value
$21.034m
$58.760m
Assets$37.726m
Liabilities$2.894m
DebtDebt to Assets
4.9%
-0.2x
Debt to EBITDAFree Cash Flow
-$15.984m
-15.9%
1y CAGR+17.3%
3y CAGR-2.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company